Genetesis

Genetesis is pioneering a novel diagnostic modality in cardiology through its CardioFlux platform, which captures and analyzes the heart's biomagnetic fields. This technology seeks to address significant shortcomings in current emergency department workflows for chest pain, offering a potential rule-out test for coronary artery disease that is fast, non-invasive, and does not expose patients to ionizing radiation. The company is positioned in the large and growing cardiovascular diagnostics market, targeting clinical adoption in hospital emergency and cardiology departments. As a private company, it has progressed through several funding rounds to advance its technology through clinical validation and regulatory pathways.

CardioFlux biomagnetic imaging system using optically pumped magnetometers (OPMs) to non-invasively map the heart's magnetic fields for detecting myocardial ischemia.

Genetesis competes with established cardiac diagnostic modalities including stress tests (echocardiography, nuclear), coronary CT angiography (CCTA), and invasive angiography. Its value proposition is based on being a non-invasive, radiation-free functional test, but it must displace these entrenched standards of care.